Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient outcomes over the past 10 years. The pace of development of new targeted therapies is accelerating, with the associated n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ionescu, Diana N., Stockley, Tracy L., Banerji, Shantanu, Couture, Christian, Mather, Cheryl A., Xu, Zhaolin, Blais, Normand, Cheema, Parneet K., Chu, Quincy S.-C., Melosky, Barbara, Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318743/
https://www.ncbi.nlm.nih.gov/pubmed/35877256
http://dx.doi.org/10.3390/curroncol29070396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318743/
https://www.ncbi.nlm.nih.gov/pubmed/35877256
http://dx.doi.org/10.3390/curroncol29070396

Ejemplares similares